Meinhardt, Anna-Lena
Munkhbaatar, Enkhtsetseg
Höckendorf, Ulrike http://orcid.org/0000-0002-8218-3343
Dietzen, Michelle http://orcid.org/0000-0002-6853-7563
Dechant, Marta
Anton, Martina http://orcid.org/0000-0001-5290-5213
Jacob, Anne
Steiger, Katja http://orcid.org/0000-0002-7269-5433
Weichert, Wilko
Brcic, Luka http://orcid.org/0000-0002-9098-8416
McGranahan, Nicholas http://orcid.org/0000-0001-9537-4045
Branca, Caterina http://orcid.org/0000-0001-6231-2040
Kaufmann, Thomas http://orcid.org/0000-0001-9906-874X
Dengler, Michael A. http://orcid.org/0000-0002-1693-1761
Jost, Philipp J. http://orcid.org/0000-0003-2454-0362
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB1335)
Deutsche Krebshilfe (112066)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (#31003A_173006)
Wellcome Trust (211179/Z/18/Z)
Article History
Received: 27 May 2021
Revised: 1 December 2021
Accepted: 16 December 2021
First Online: 29 January 2022
Competing interests
: KS has received funding from Roche Pharma AG and is a member of the scientific advisory board of TRIMT GmbH. WW has attended Advisory Boards and served as a speaker for Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Amgen, and Astellas. WW receives research funding from Roche, MSD, BMS, and Bruker. LB has had a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from Abbvie, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, MSD, Merck, Novartis, Pfizer, Roche, and Takeda. NM has stock options and has received consultancy fees from Achilles Therapeutics. PJJ has had a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from Abbvie, Roche, BMS Celgene, Boehringer, Novartis, Pfizer, Pierre Fabre, and Servier. TK is a co-founder and shareholder of ATANIS Biotech AG, a company performing allergy diagnosis. All the other authors disclose no potential conflicts of interest.